Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3′,5′ guanosine monophosphate (cGMP) level in podocytes

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1751-1761

  Fang, Lilla ^a   Radovits, Tamás ^a,b   Szabó, Gábor ^b   Mózes, Miklós M ^a   Rosivall, László ^a   Kökény, Gábor ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cyclic GMP; Phoshopdiesterase 5; Podocyte; TGF 1; Type 1 diabetes

Indexed keywords

3 NITROTYROSINE; BIOLOGICAL MARKER; CYCLIC GMP; DESMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRONECTIN; NEPHRIN; NEURONAL NITRIC OXIDE SYNTHASE; PODOCIN; TRANSFORMING GROWTH FACTOR BETA1; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL DAMAGE; CELL LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY HYPERTROPHY; KIDNEY INJURY; MALE; NEPHRIN GENE; NONHUMAN; OXIDATIVE STRESS; PODOCIN GENE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT;

CYCLIC GMP; PHOSHOPDIESTERASE-5; PODOCYTE; TGF-Β1; TYPE 1 DIABETES;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PODOCYTES; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONES; TRANSFORMING GROWTH FACTOR BETA1; TRIAZINES;

EID: 84884505854     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs391     Document Type: Article

References (50)

1. ERA-EDTA. ERA-EDTA Registry Annual Report 2008. Amsterdam, The Netherlands: Academic Medical Center, Department of Medical Informatics, 2010
2. USRDS. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. MD: National Institutes of Health Bethesda, U.S. Renal Data System, 2010
3. Suzuki D, Miyata T, Saotome N et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999; 10: 822-832
4. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634
5. Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int 1994; 45: 612-622
6. Ballermann BJ, Marsden PA. Endothelium-derived vasoactive mediators and renal glomerular function. Clin Invest Med 1991; 14: 508-517
7. Knight S, Snellen H, Humphreys M et al. Increased renal phosphodiesterase- 5 activity mediates the blunted natriuretic response to ANP in the pregnant rat. Am J Physiol Renal Physiol 2007; 292: F655-F659
8. Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48: 20-32
9. Pavenstadt H. Roles of the podocyte in glomerular function. Am J Physiol Renal Physiol 2000; 278: F173-F179
10. Sharma R, Lovell HB, Wiegmann TB et al. Vasoactive substances induce cytoskeletal changes in cultured rat glomerular epithelial cells. J Am Soc Nephrol 1992; 3: 1131-1138
11. Craven PA, Studer RK, DeRubertis FR. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. J Clin Invest 1994; 93: 311-320
12. Pacher P, Obrosova IG, Mabley JG et al. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 2005; 12: 267-275
13. Dousa TP. Cyclic-30,50-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 1999; 55: 29-62
14. Matousovic K, Tsuboi Y, Walker H et al. Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid. J Lab Clin Med 1997; 130: 487-495
15. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V et al. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int 2005; 68: 2131-2142
16. Dousa TP. Signaling role of PDE isozymes in pathobiology of glomerular mesangial cells. Studies in vitro and in vivo. Cell Biochem Biophys 1998; 29: 19-34
17. Ghali-Ghoul R, Tahseldar-Roumieh R, Sabra R. Effect of chronic administration of sildenafil on sodium retention and on the hemodynamic complications associated with liver cirrhosis in the rat. Eur J Pharmacol 2007; 572: 49-56
18. Lledo-Garcia E, Rodriguez-Martinez D, Cabello-Benavente R et al. Sildenafil improves immediate posttransplant parameters in warm-ischemic kidney transplants: experimental study. Transplant Proc 2007; 39: 1354-1356
19. Lau DH, Mikhailidis DP, Thompson CS. The effect of vardenafil (a PDE type 5 inhibitor) on renal function in the diabetic rabbit: a pilot study. In Vivo 2007; 21: 851-854
20. Jeong KH, Lee TW, Ihm CG et al. Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am J Nephrol 2009; 29: 274-282
21. Kuno Y, Iyoda M, Shibata T et al. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulindependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol 2011; 162: 1389-1400
22. Lee HS. Pathogenic role of TGF-beta in the progression of podocyte diseases. Histol Histopathol 2011; 26: 107-116
23. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67: 799-812
24. el Nahas AM, Zoob SN, Evans DJ et al. Chronic renal failure after nephrotoxic nephritis in rats: contributions to progression. Kidney Int 1987; 32: 173-180
25. Piecha G, Kokeny G, Nakagawa K et al. Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 2008; 294: F748-F757
26. Hirschberg K, Radovits T, Loganathan S et al. Selective phosphodiesterase- 5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical endarterectomy. J Thorac Cardiovasc Surg 2009; 137: 1508-1514
27. Floege J, Kriz W, Schulze M et al. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 1995; 96: 2809-2819
28. Vaziri ND, Ni Z, Oveisi F et al. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 39: 135-141
29. Goldstein I, Young JM, Fischer J et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26: 777-783
30. Zhao HJ, Wang S, Cheng H et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006; 17: 2664-2669
31. Han DC, Hoffman BB, Hong SW et al. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol 2000; 278: F628-F634
32. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020
33. Floege J, Alpers CE, Burns MW et al. Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Lab Invest 1992; 66: 485-497
34. Wolf G, Schroeder R, Zahner G et al. High glucose-induced hypertrophy of mesangial cells requires p27(Kip1), an inhibitor of cyclin-dependent kinases. Am J Pathol 2001; 158: 1091-1100
35. Yevdokimova N, Wahab NA, Mason RM. Thrombospondin-1 is the key activator of TGF-beta1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol 2001; 12: 703-712
36. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008; 74: 22-36
37. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003; 93: P3-P13
38. Abbate M, Zoja C, Morigi M et al. Transforming growth factorbeta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002; 161: 2179-2193
39. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M et al. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002; 62: 901-913
40. Han SH, Yang S, Jung DS et al. Gene expression patterns in glucose-stimulated podocytes. Biochem Biophys Res Commun 2008; 370: 514-518
41. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003; 23: 532-543
42. Dessapt C, Baradez MO, Hayward A et al. Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrol Dial Transplant 2009; 24: 2645-2655
43. Wu DT, Bitzer M, Ju W et al. TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 2005; 16: 3211-3221
44. Putaala H, Soininen R, Kilpelainen P et al. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet 2001; 10: 1-8
45. Roselli S, Heidet L, Sich M et al. Early glomerular filtration defect and severe renal disease in podocin-deficient mice. Mol Cell Biol 2004; 24: 550-560
46. Wang S, Skorczewski J, Feng X et al. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factorbeta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem 2004; 279: 34311-34322
47. Hohenstein B, Daniel C, Wittmann S et al. PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis. Nephrol Dial Transplant 2008; 23: 3427-3436
48. Roumeguere T, Zouaoui Boudjeltia K, Babar S et al. Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified lowdensity lipoprotein or tumor necrosis factor alpha. Eur Urol 2010; 57: 522-528
49. Milani E, Nikfar S, Khorasani R et al. Reduction of diabetesinduced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 2005; 140: 251-255
50. 2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int 2005; 96: 423-427